|
US6184024B1
(en)
*
|
1988-07-14 |
2001-02-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric and/or growth-restricted flaviviruses
|
|
US6254873B1
(en)
|
1995-04-17 |
2001-07-03 |
The United States Of America As Represented By The Secretary Of The Army |
Inactivated dengue virus vaccine
|
|
US6190859B1
(en)
|
1995-04-17 |
2001-02-20 |
The United States Of America As Represented By The Secretary Of The Army |
Method and kit for detection of dengue virus
|
|
AU6093296A
(en)
|
1995-06-07 |
1996-12-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Infectious dengue 2 virus pdk-53 as quadravalent vaccine
|
|
EP0836090A1
(en)
|
1996-10-12 |
1998-04-15 |
Evotec BioSystems GmbH |
Method of analysis of samples by determination of the distribution of specific brightnesses of particles
|
|
CA2282790C
(en)
|
1997-02-28 |
2011-04-19 |
St. Louis University |
Chimeric flavivirus vaccines
|
|
KR20010022452A
(ko)
|
1997-07-31 |
2001-03-15 |
추후제출 |
플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
|
|
AU774045B2
(en)
|
1998-09-02 |
2004-06-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Dengue viruses that are replication defective in mosquitos for use as vaccines
|
|
AU4179200A
(en)
|
1999-03-26 |
2000-10-16 |
Walter Reed Army Institute Of Research |
Attenuated dengue-1 virus vaccine
|
|
AU779280B2
(en)
|
1999-03-26 |
2005-01-13 |
Walter Reed Army Institute Of Research |
Multivalent dengue virus vaccine
|
|
CA2365411A1
(en)
|
1999-03-26 |
2000-10-05 |
Walter Reed Army Institute Of Research |
Attenuated dengue-2 virus vaccine
|
|
US6537557B1
(en)
|
1999-03-26 |
2003-03-25 |
The United States Of America As Represented By The Secretary Of The Army |
Attenuated dengue-4 virus vaccine
|
|
US6432411B1
(en)
|
1999-07-13 |
2002-08-13 |
Hawaii Biotechnology Group |
Recombinant envelope vaccine against flavivirus infection
|
|
EP1402075B1
(en)
|
2001-05-22 |
2012-11-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, |
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
|
|
JP2005519639A
(ja)
|
2002-01-15 |
2005-07-07 |
アカンビス インコーポレーティッド |
フラビウイルスワクチン
|
|
HUE037330T2
(hu)
|
2002-05-03 |
2018-08-28 |
The Government Of The Us Secretary Department Of Health And Human Services |
rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
|
|
AU2003239932A1
(en)
|
2002-05-31 |
2003-12-19 |
Acambis, Inc. |
Tetravalent dengue vaccines
|
|
US7189403B2
(en)
|
2003-06-30 |
2007-03-13 |
Institut Pasteur |
Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
|
|
AU2004304770B2
(en)
|
2003-12-08 |
2010-05-06 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
|
WO2006044857A2
(en)
|
2004-10-20 |
2006-04-27 |
Acambis Inc. |
Vaccines against japanese encephalitis virus and west nile virus
|
|
BRPI0613287A2
(pt)
|
2005-06-17 |
2010-12-28 |
Sanofi Pasteur |
cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
|
|
WO2006134433A1
(en)
|
2005-06-17 |
2006-12-21 |
Sanofi Pasteur |
Dengue serotype 1 attenuated strain
|
|
BRPI0611581B1
(pt)
|
2005-06-24 |
2021-08-03 |
Intervet International B.V. |
Flavivírus quimérico inativado, composição imunogênica, e, vacina
|
|
US8017754B2
(en)
|
2005-07-22 |
2011-09-13 |
Research Development Foundation |
Attenuated virus strains and uses thereof
|
|
US7470674B2
(en)
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
AR061197A1
(es)
|
2006-06-07 |
2008-08-13 |
Sanofi Pasteur |
Cepas del virus 3 del dengue vivas atenuadas
|
|
DK2589602T3
(en)
*
|
2006-08-15 |
2016-07-25 |
The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of |
Development of dengue virus vaccine components
|
|
FR2906724B1
(fr)
|
2006-10-04 |
2009-03-20 |
Sanofi Pasteur Sa |
Methode d'immunisation contre les 4 serotypes de la dengue.
|
|
US8440202B2
(en)
|
2006-11-09 |
2013-05-14 |
The United States Of America As Represented By The Secretary Of The Navy |
Induction of an immune response against dengue virus using the prime-boost approach
|
|
ES2517615T3
(es)
|
2006-11-09 |
2014-11-03 |
The United States Of America As Represented By The Secretary Of The Navy |
Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
|
|
BRPI0904020B8
(pt)
*
|
2009-10-01 |
2021-05-25 |
Fundacao Oswaldo Cruz |
composição vacinal contra o vírus da dengue, e, kit
|
|
WO2012154202A1
(en)
*
|
2010-10-29 |
2012-11-15 |
Merck Sharp & Dohme Corp. |
Recombinant subunit dengue virus vaccine
|
|
US20120294889A1
(en)
*
|
2010-11-12 |
2012-11-22 |
Paxvax, Inc. |
Chimeric Flavivirus Vaccines
|
|
CA2878599A1
(en)
*
|
2012-07-24 |
2014-01-30 |
Jiansheng Yao |
Vaccine compositions for prevention against dengue virus infection
|
|
MX366154B
(es)
|
2013-06-21 |
2019-06-28 |
Merck Sharp & Dohme |
Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
|